Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-920

Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-920-1mg 1mg 3090
GMP-Bios-INN-920-10mg 10mg Inquiry
GMP-Bios-INN-920-100mg 100mg Inquiry
GMP-Bios-INN-920-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A
INN Name Moxetumomab Pasudotox
TargetCD22
FormatFusion Protein
DerivationMus musculus
Species Reactivityhuman
CH1 IsotypeFv - disulfide stabilized
VD LCFv - disulfide stabilized
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesMedImmune (Gaithersburg MD USA) / AstraZeneca (London UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development TechCambridge Antibody Technology (CAT) human antibody phage display library